papers/russler-germainMutationsAssociatedProgression2023.md
... ...
@@ -4,6 +4,34 @@ bibliography: 'morinlab.bib'
4 4
---
5 5
6 6
# @russler-germainMutationsAssociatedProgression2023
7
+
8
+## Study Overview
9
+In their 2023 study published in *Blood Advances*, Russler-Germain et al. conducted a comprehensive clinicogenomic analysis of 370 patients with follicular lymphoma (FL) or transformed FL (t-FL). The research aimed to elucidate the relationship between genetic alterations and patient outcomes, particularly focusing on mutations associated with disease progression. ([Source](https://ashpublications.org/bloodadvances/article/7/18/5524/497092/Mutations-associated-with-progression-in))
10
+
11
+## Key Findings
12
+
13
+### Mutation Burden
14
+- No significant differences in mutation burden were observed among FL subsets categorized by grade, stage, watch-and-wait approach, or progression of disease within 24 months (POD24) status.
15
+- However, mutation burden was notably higher in relapsed/refractory FL and t-FL compared to newly diagnosed FL.
16
+
17
+### Specific Gene Mutations
18
+- **CREBBP** mutations were more prevalent in FL than in t-FL and were associated with shorter frontline progression-free survival (PFS) in FL patients.
19
+- Mutations in *STAT6*, *TP53*, *IGLL5*, *B2M*, *SOCS1*, and *MYD88* were more common in relapsed/refractory FL or t-FL than in newly diagnosed FL.
20
+
21
+### Mutations Associated with Progression (MAP) Signature
22
+- The MAP signature was defined as the presence of two or more mutations among the seven genes: *CREBBP*, *STAT6*, *TP53*, *IGLL5*, *B2M*, *SOCS1*, and *MYD8**.
23
+- Patients with newly diagnosed FL possessing a MAP signature exhibited shorter frontline PFS, indicating a higher risk of disease progression.
24
+
25
+## Clinical Implications
26
+- The MAP signature may offer insights into FL progression risk, potentially providing a more generalizable prognostic tool than the m7-Follicular Lymphoma International Prognostic Index (m7-FLIPI).
27
+- Identifying patients with a MAP signature at diagnosis could facilitate the development of targeted therapeutic strategies and inform clinical decision-making.
28
+
29
+---
30
+
31
+## Conclusion
32
+Russler-Germain et al.'s study enhances the understanding of the genetic factors influencing FL progression. The identification of a MAP signature associated with inferior outcomes at diagnosis underscores the importance of genetic profiling in FL and highlights the potential for personalized treatment approaches in managing this heterogeneous disease.
33
+
34
+
7 35
## Summary of novel genes
8 36
9 37
|Entity| Tier 1 genes| Tier 2 genes|Tier 3 genes|